Oncopeptides shares plunge on early study data despite CEO's 'breakthrough' claim

Oncopeptides' stock fell sharply after presenting initial patient data from an ongoing study, despite CEO Sofia Heigis calling it a major breakthrough. The market's negative reaction suggests the data may have disappointed expectations or raised safety/efficacy concerns. This is a company-specific event with no broader market implications.